Phathom Pharmaceuticals, Inc. Non-operating Income/Expense

Non-operating Income/Expense of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Income/Expense growth rates and interactive chart. Income or expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from operating expenses.


Highlights and Quick Summary

  • Non-operating Income/Expense for the quarter ending September 29, 2021 was $-2.05 Million (a -20580.0% decrease compared to previous quarter)
  • Year-over-year quarterly Non-operating Income/Expense increased by 102300.0%
  • Annual Non-operating Income/Expense for 2020 was $-3.4 Million (a -97.71% decrease from previous year)
  • Annual Non-operating Income/Expense for 2019 was $-149 Million (a 236274.6% increase from previous year)
  • Twelve month Non-operating Income/Expense ending September 29, 2021 was $-2.04 Million (a -68133.33% decrease compared to previous quarter)
  • Twelve month trailing Non-operating Income/Expense increased by 139.55% year-over-year
Trailing Non-operating Income/Expense for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$-2.04 Million $3 Thousand $-1.09 Million $-852 Thousand
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Income/Expense of Phathom Pharmaceuticals, Inc.

Most recent Non-operating Income/Expenseof PHAT including historical data for past 10 years.

Interactive Chart of Non-operating Income/Expense of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Non-operating Income/Expense for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-2.05 $0.01 $-0.0
2020 $-0.0 $-0.0 $-1.08 $0.23 $-3.4
2019 $-82.31 $-61.83 $-4.75 $-0.03 $-148.92
2018 $-0.02 $-0.06

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.